Otulfi

Drug Overview

In the specialized field of Gastroenterology, the treatment of chronic inflammatory conditions has been transformed by the development of Targeted Therapy. Otulfi represents a significant milestone in this journey as a high-performance Biologic medication. Specifically, Otulfi is a Monoclonal Antibody and is classified as a Ustekinumab Biosimilar. This means it is highly similar to the original reference product (Stelara) with no clinically meaningful differences in safety or effectiveness. As an IL-12/23 Inhibitor, Otulfi offers a sophisticated way to calm an overactive immune system in patients dealing with moderately to severely active inflammatory bowel disease (IBD).

IBD, which includes Crohn’s Disease and Ulcerative Colitis, often requires a “bridge” to long-term health when traditional medicines fail. Otulfi provides this bridge by blocking specific proteins in the body that cause the digestive tract to become swollen and painful. Because it is a Biosimilar, it helps increase access to life-changing Biologic therapy for international patients, offering a more sustainable option for healthcare systems in the US and European markets.

• Generic Name: Ustekinumab-aauz
• US Brand Names: Otulfi
• Route of Administration: Initial treatment begins with a single Intravenous (IV) Infusion, followed by a Maintenance Phase of Subcutaneous (SC) Injections.
• FDA Approval Status: FDA-approved (2024) for the treatment of Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis.

What Is It and How Does It Work? (Mechanism of Action)

Otulfi is a small-molecule protein designed to act like a precision key that fits into a specific lock. To understand how it works at the molecular level, we must look at how the immune system communicates. In people with IBD, the body produces too much of two specific “messenger” proteins called cytokines: Interleukin-12 (IL-12) and Interleukin-23 (IL-23). These cytokines are responsible for telling the body to attack its own intestinal lining.

IL-12 and IL-23 both share a common component called the p40 subunit. Otulfi is a human Monoclonal Antibody that is specifically engineered to find and bind to this p40 subunit. When Otulfi attaches to this protein, it acts as a shield. It prevents IL-12 and IL-23 from binding to their receptors on the surface of immune cells (such as T-cells).

This process is a form of “cytokine modulation.” By blocking these signals, Otulfi stops the immune system from activating two primary pathways: the Th1 and Th17 inflammatory pathways. When these pathways are silenced, the “fire” of inflammation in the gut begins to go out. This reduction in chemical signaling allows for Mucosal Healing, where the ulcers in the colon or small intestine finally have a chance to repair themselves. By strengthening the intestinal epithelial barrier, Otulfi helps restore the body’s natural defense against bacteria, leading to a long-term reduction in symptoms like diarrhea, pain, and bleeding.

FDA-Approved Clinical Indications

Otulfi is utilized to restore digestive health in patients who have not responded well to, or cannot tolerate, other medications like corticosteroids or TNF-blockers.

• Primary Indication: Moderately to Severely Active Crohn’s Disease: Specifically used for adult patients to achieve and maintain clinical remission. It helps reduce the inflammation that can occur anywhere in the digestive tract.
• Primary Indication: Moderately to Severely Active Ulcerative Colitis: Indicated for adult patients to improve the health of the colon lining and reduce the frequency of bowel movements and rectal bleeding.

Primary Gastroenterology Indications:

• Induction of Remission: Using a high-dose IV infusion to quickly lower the inflammation levels in the gut.
• Maintenance of Remission: Using regular subcutaneous injections to keep the disease “asleep” (remission) and prevent future flares.
• Mucosal Healing: Promoting a physical state where the intestinal lining looks healthy during an endoscopy or colonoscopy.

Other Approved & Off-Label Uses:

• Plaque Psoriasis: Treatment of moderate to severe skin plaques in adults and pediatric patients (6 years and older).
• Psoriatic Arthritis: Used to reduce joint pain and swelling in adults.
• Eosinophilic Esophagitis (Off-label): Some research areas explore its use in other immune-mediated digestive disorders where IL-23 plays a role.

Dosage and Administration Protocols

The administration of Otulfi is unique because it combines two different methods. The first dose is designed to “jump-start” the healing process, while the following doses are for long-term protection.

Indication	Standard Dose	Frequency
IBD Induction (Initial)	Weight-based IV (e.g., 260 mg to 520 mg)	Single IV Infusion at Week 0
IBD Maintenance	90 mg Subcutaneous (SC)	Every 8 weeks starting at Week 8
Plaque Psoriasis	45 mg or 90 mg (SC)	Week 0, Week 4, then every 12 weeks

Dose Adjustments and Special Populations:

• Hepatic/Renal Insufficiency: No specific dose adjustments are required for patients with liver or kidney issues, as Monoclonal Antibody treatments are not processed by these organs in the same way as traditional drugs.
• Pediatric Population: For IBD, safety has not been fully established in children, though it is approved for skin conditions in children as young as 6.
• Elderly Patients: Standard dosing is typically used, but close monitoring for infection is required.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

As a Biosimilar, Otulfi was required to prove it works exactly like the reference product in clinical trials. Research data from 2020 through 2026 confirms that ustekinumab-based therapies are highly effective. In pivotal clinical trials for Crohn’s Disease (the UNITI trials), approximately 34% to 40% of patients achieved clinical remission within just 8 weeks of the initial IV dose.

Numerical data regarding Mucosal Healing is particularly impressive. In the UNIFI trial for Ulcerative Colitis, approximately 53% of patients showed significant improvement in the appearance of their intestinal lining by Week 8. Long-term research shows that for patients who stay on the maintenance dose, roughly 43% remain in clinical remission after one full year. These trials also utilized the Mayo Score (for UC) and the CDAI (for Crohn’s) to track success, showing that Otulfi helps patients achieve “steroid-free remission,” which is a primary goal in modern Gastroenterology.

Safety Profile and Side Effects

There are no Black Box Warnings for Otulfi. However, because this drug calms the immune system, it can make it slightly harder for the body to fight off certain infections.

Common Side Effects (>10%)

• Nasopharyngitis (Common cold symptoms).
• Upper respiratory tract infections.
• Headache.
• Abdominal pain and fatigue.
• Redness or itching at the injection site.

Serious Adverse Events

• Serious Infections: Such as tuberculosis (TB), fungal infections, or bacterial pneumonia.
• Malignancies: A theoretical slight increase in the risk of certain cancers, including non-melanoma skin cancer.
• Posterior Reversible Encephalopathy Syndrome (PRES): A very rare brain condition characterized by headache, confusion, and seizures.
• Non-infectious Pneumonia: Rare inflammation of the lungs.

Management Strategies: Patients must be screened for TB before starting treatment. If an infection occurs, the doctor may pause the medication. Regular skin exams are recommended to monitor for any unusual growths.

Research Areas

In the 2025-2026 research window, Gastroenterology is focusing heavily on how Otulfi interacts with the gut microbiome. IL-23 is known as the “gatekeeper” of the gut’s immune response. When Otulfi blocks IL-23, it doesn’t just stop inflammation; it may also help the gut-associated lymphoid tissue (GALT) return to a healthy state.

Current Research Areas include:

• Microbiome Diversity: Investigating if patients who achieve Mucosal Healing on Otulfi also see a return of “good” bacteria like Faecalibacterium prausnitzii.
• Oral Formulations: While currently an injection, there are active clinical trials for oral Targeted Therapy options that work on the same IL-23 pathway.
• Therapeutic Drug Monitoring (TDM): Studying the best “trough levels” of the drug in the blood to ensure patients don’t lose response over time.

Disclaimer: The research described regarding Otulfi is currently based on emerging studies, exploratory findings, and ongoing clinical investigations, and is not yet fully validated for routine clinical application or established professional medical practice scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: A colonoscopy or endoscopy to visualize the current state of the gut.
• Organ Function: Baseline Liver Function Tests (LFTs) and blood counts.
• Specialized Testing: Mandatory screening for latent Tuberculosis (TB) and Hepatitis B.
• Screening: Checking for recent “Live” vaccines. Patients should receive all necessary vaccinations before starting Otulfi.

Monitoring and Precautions

• Vigilance: Monitoring for “loss of response.” If symptoms return, a doctor may check for “anti-drug antibodies.”
• Lifestyle: Encouraging a high-fiber diet (when not in a flare) and plenty of hydration. Smoking cessation is critical, especially for Crohn’s patients.
• Do’s and Don’ts:
  • DO keep your injections on a strict schedule.
  • DO report any fever or persistent cough immediately.
  • DON’T receive live vaccines (like the shingles or yellow fever vaccine) during treatment.
  • DON’T stop the medication just because you feel better; IBD is a chronic condition.

Legal Disclaimer

The medical information provided in this guide is for informational purposes only and does not replace professional medical advice from a qualified healthcare provider. Otulfi is a potent Biologic medication that must be used under the supervision of a specialist. If you experience signs of a severe allergic reaction, such as trouble breathing or swelling of the face, seek emergency medical attention immediately. Always consult your gastroenterologist before starting any new treatment plan. High-potency therapy must be individualized based on the patient’s specific disease history and clinical profile.